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Successful use of entecavir for a severe case of reactivation
of hepatitis B virus following polychemotherapy containing rituximabq
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3Hospital Vall d’Hebron, Hematology Division, Barcelona, SpainBackgrounds/Aims:Hepatitis B virus (HBV) reactivation following treatment with rituximab has been reported in
patients with either HBsAg-positive, or HBsAg-negative and anti-HBc positive infection. Patients with severe reactivation
often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with
severe HBV reactivation.
Methods:We present a case of a HBsAg-negative patient diagnosed with chronic lymphocytic leukemia who received a
chemotherapeutic regimen that included rituximab, who subsequently presented with severe HBV reactivation with ascites,
jaundice and coagulopathy and was treated with entecavir. A review of the literature and underlying HBV associated muta-
tions are discussed.
Results:Entecavir produced a rapid and sustained suppression of HBV that was associated with rapid clinical improve-
ment without any side eﬀects.
Conclusion:Entecavir is an eﬃcacious and safe treatment for severe HBV reactivation.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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antigen.occur in two settings: in chronic carriers of hepatitis B
surface antigen (HBsAg) and in patients with prior
HBV infection who are HBsAg-negative and have anti-
bodies against hepatitis B core antigen (anti-HBc) with
or without antibodies to hepatitis B surface antigen
(anti-HBs) [1,2]. HBV reactivation has important clini-
cal and therapeutic implications; however, there is no
clear consensus in the guidelines regarding HBV screen-
ing and management [3,4].
The consensus guidelines issued by the American
Association for the Study of Liver Diseases (AASLD)
recommend screening with HBsAg in patients at high
risk for hepatitis B infection prior to the initiation of
chemotherapy and prophylaxis for those who are
HBsAg-positive. They do not recommend anti-HBc
screening or prophylaxis for individuals who are
HBsAg-negative or for those who are anti-HBc positive,Published by Elsevier B.V. All rights reserved.
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ment of Hepatitis B guidelines issued by the European
Association for the Study of the Liver (EASL) recom-
mend screening of all the candidates for chemotherapy
and immunosuppressive therapy with HBsAg and anti-
HBc antibodies prior to initiation of treatment [4].
According to these guidelines, prophylaxis against
HBV reactivation is only recommended for patients
who are HBsAg-positive. For those who are anti-HBc
positive with an undetectable serum HBV-DNA, they
recommend following serum alanine transaminase
(ALT) and HBV-DNA level and to start antiviral ther-
apy if and when there is evidence of HBV reactivation.
The same guidelines recommend prophylaxis and treat-
ment with lamivudine, but mention that entecavir and
tenofovir should be considered in patients with high lev-
els of HBV-DNA, though the experience in this setting
with these medications is very limited.
We describe a case of severe HBV reactivation with
decompensated liver disease in an HBsAg-negative
patient who received a chemotherapeutic regimen that
included rituximab and ﬂudarabine for treatment of
chronic lymphocytic leukemia, and who was successfully
treated with entecavir, achieving a rapid and sustained
suppression of HBV replication.2. Case report
A 62 year-old male was diagnosed in May 2007 with
chronic lymphocytic leukemia. He initially presented
with Rai Stage 0, and was managed with observation
until August 2008, when he developed cervical lymphad-
enopathy and was considered for chemotherapy. He had
no history of liver disease and prior to initiating chemo-
therapy his liver enzymes were normal, HBsAg was neg-
ative and anti-HBc positive and anti-HBs were not
determined. Therefore, no HBV prophylaxis was initi-
ated. From September to November 2008 the patient
was treated with four cycles of polychemotherapy (ritux-
imab, ﬂudarabine and cyclophosfamide), which resulted
in complete tumoral remission. In December 2008, 4
weeks after the last cycle, his liver enzymes were abnor-
mal with an AST 121 IU/L (normal <40.0 IU/L), ALT
257 IU/L (normal <44.0 IU/L) and normal alkaline
phosphatase and total bilirubin. These elevations were
thought to be related to chemotherapy and no interven-
tion was undertaken. Two months later, the patient pre-
sented with fatigue, jaundice and ascites. On physical
exam, the patient was alert and oriented, with signiﬁcant
jaundice, hepatosplenomegaly and ascitic, without aster-
ixis. A paracentesis was performed. The ascites ﬂuid was
translucent with a protein of 0.7 g/dL, and showed no
evidence of infection. Laboratory tests showed an
increase in transaminases activity with an AST of
2180 IU/L, and an ALT of 3481 IU/L, total bilirubinand direct bilirubin were 10.29 mg/dL (normal
<1.02 mg/dL), and 8.41 mg/dL (normal <0.57 mg/dL)
respectively, creatinine was 1.49 mg/dL (normal
<1.3 mg/dL) and INR was prolonged at 1.82. Hepatitis
B serology showed HBsAg-positive, anti-HBc IgM neg-
ative, HBeAg negative, and anti-HBeAg positive. HBV-
DNA level of 8.6  107 IU/mL, measured by PCR
(COBAS TaqMan HBV test (Roche Diagnostics, Basel,
Switzerland) with a limit of detection of 12 IU/mL.
Other viral markers such as antibodies against hepatitis
C virus (HCV) and hepatitis A virus IgM were negative.
On February 12, 2009, the patient was started on
antiviral therapy with entecavir (Baraclude Bristol-
Myers Squibb) at a dose of 0.5 mg orally per day for
HBV reactivation. Figs. 1 and 2 show the course of lab-
oratory tests, including albumin serum levels, HBV-
DNA levels, and HBsAg quantiﬁcation during treat-
ment with entecavir. Treatment was well tolerated and
no side eﬀects were observed. After 3 months of enteca-
vir treatment, the patient was asymptomatic and his lab
results showed HBsAg-positive, ALT 19 mg/dL, and
undetectable HBV-DNA.
Complete molecular analysis of the HBV was per-
formed prior to starting entecavir treatment, with ampli-
ﬁcation by nested PCR of the core gene, the surface gene
and reverse transcriptation (RT) region of the polymer-
ase gene as previously described [5]. The molecular
results showed that the patient was infected with HBV
genotype D and mutation G1896A within the pre-core
region. Aminoacids from 99 to 160 of the surface gene,
which include the main immunodominant epitope ‘‘a”
region, were analyzed and the following changes:
S122R, S127P, S134Y, S159G, and S160K were noted
in relation to genotype D consensus surface region. In
addition, mixed sequences were observed at positions
L104LV and L109LI. At the polymerase gene, no muta-
tions conferring drug resistance were detected. HBsAg
was quantiﬁed using the Architect HBsAg assay (Abbott
Laboratories, Abbott Park, IL; dynamic range, 0.05–
250.0 IU/mL) after 1/100, 1/2 dilution and non-dilution
of each sample (Fig. 1).3. Discussion
HBV reactivation is more frequent in patients with
chronic HBV infection. However, it can also occur in
patients who have resolved the infection, as indicated
by the presence of anti-HBc and/or anti-HBs, known
as ‘‘de novo hepatitis B.” Although ‘‘de novo hepatitis
B” occurs only in 3.3–4% of patients after chemother-
apy, it is an increasing concern to clinicians because of
its higher morbidity and mortality rate [6,7]. HBV reac-
tivation usually occurs in patients after solid organ
transplant, allogenic and autologous hematopoietic
stem-cell transplantation, and after immunosuppressive
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Fig. 1. Biochemical parameters before and during entecavir treatment.
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deﬁned as detectable HBV-DNA and elevated ALT lev-
els during and up to 6 months after completion of che-
motherapy was detected in 5 (25%) of 21 patients
treated with rituximab and in none of those treated
without rituximab [12]. In addition, due to the increas-
ing reports the United States Food and Drug Adminis-
tration emitted a black box warning regarding the risk
of hepatic dysfunction when using this medication [13].
To our knowledge, this is the ﬁrst case of severe HBV
reactivation leading to hepatic decompensation success-
fully treated with entecavir. In this case, entecavir
achieved a rapid and complete viral suppression despite
very high levels of HBV-DNA and the delay in its
administration due to late diagnosis. The treatment also
led to reversal of decompensation without any adverse
eﬀects. Upon review of the literature, only one case of
HBV reactivation treated with entecavir as ﬁrst-line
therapy has been published [14] and, in contrast with
our patient, this patient was asymptomatic with only
an increase in ALT activity and without jaundice and
liver decompensation. Table 1 summarizes a literature
review of 15 cases of HBV reactivation following a che-
motherapeutic regimen including rituximab who were
treated with oral antivirals. Like our case, the majority
were anti-HBc positive, had elevated ALT peaks after
a median of 4–5 cycles of treatment and 10 died of liver
related complications despite lamivudine treatment.
In our patient, entecavir was chosen as initial treat-
ment, taking into consideration the high mortality rate
during lamivudine therapy and the presence of high lev-
els of HBV-DNA associated with a negative HBeAg,
factors that suggested that a long, even indeﬁnite, treat-
ment, could be necessary. Entecavir oﬀers advantages
over lamivudine, as has been demonstrated in several
studies [15]. Entecavir achieves a faster and stronger
HBV-DNA suppression than lamivudine and has a high
resistance barrier, which is important in a long treat-
ment course. In cases of HBV reactivation the presence
of HBV precore mutations, G1986A, such as the one
present in our patient, has been associated with the
development of severe hepatitis, including fulminant
hepatitis [16]. This virulence could be explained by the
loss of the immunomodulatory eﬀect associated with
the HBeAg, which cannot be produced by the presence
of this mutation and suggests that in patients with
HBV reactivations carrying the pre-core mutations,
more potent antiviral drugs like entecavir and tenofovir
should be used to prevent the development of severe
liver complications.
Moreover, the presence of several aminoacid changes
in the ‘‘a” determinant of HBV surface region known to
impair HBsAg antigenicity, as detected in our case, are
more frequent in cases of HBV reactivation, which
may suggest some mismatch eﬀect between HBsAgand anti-HBs antibodies, assuming that antibodies were
present prior to HBV reactivation [17].
Rituximab aﬀects both the cellular and the humoral
arms of the immune system. In fact, it has been shown
that besides depleting the circulating population of B
cells, it increases both activated and regulatory T cells
[18]. After the disappearance of B cells from the circula-
tion, and elimination of the previously formed antibod-
ies, disequilibrium in the immunological response in
patients with a history of exposure to hepatitis B may
occur and this would allow for viral replication and
reactivation of HBV infection. In the majority of cases,
Rituximab is given concomitantly with other drugs
which also have immunomodulatory eﬀects producing
an enhanced immunosuppression. In this case, ﬂudara-
bine was used concomitantly and there have been
reports of HBV reactivation with this drug [19,20]. Flu-
darabine produces a pronounced decreased in the T cells
populations, which for CD4+ cells is still present up to
13 months after the end of therapy [21].
It is at this state where the conditions are favorable
for HBV proliferation, evidenced by increased serum
HBV-DNA but without clinical or biochemical evidence
of hepatitis (akin to the state of immune tolerance in
newborns). The restoration of immune function follow-
ing withdrawal of chemotherapy would lead to rapid
cytolysis of infected hepatocytes and hence hepatitis
and liver damage. This could be an explanation for the
lag seen between the chemotherapy and hepatitis mani-
festations [22,23].
From the currently available literature, it is apparent
that reactivation of hepatitis B virus infection following
chemotherapy treatment (‘‘de novo” hepatitis B) can be
severe and associated with high fatality. We pointed out
before that the AASLD only recommended screening of
these patients with HBsAg. By following this recommen-
dation, we would be missing patients with HBsAg-nega-
tive and anti-HBc positive infection who are also at risk
of reactivation.We believe that patients being considered
for chemotherapy should be screened for hepatitis B
infection with HBsAg, anti-HBs and anti-HBc, and if
needed, subsequent HBV-DNA determination.
In those patients with negative HBV-DNA levels in
serum, periodic determination of HBV-DNA levels
and liver enzymes during treatment should be carried
out and antiviral treatment should be instituted if the
HBV-DNA level is detected, as prompt treatment initia-
tion seems to have an impact on the clinical course. For
patients with positive HBV-DNA levels, prophylaxis
should be implemented before the start of the chemo-
therapeutic regimen with lamivudine or entecavir and
continue at least for 12 months after cessation of chemo-
therapy. In the case of severe reactivation, we recom-
mend treatment with entecavir as a ﬁrst option due to
its greater eﬃcacy in decreasing the HBV levels.
Table 1
Baseline characteristics and clinical outcome of patients treated with oral antiviral for HBV reactivation following a chemotherapy regimen containing
rituximab reported in the literature.
Author Age
(Yrs)
Sex Baseline
disease
HBV serologya
pre-
chemotherapy
Chemotherapy
treatment
Peak
ALT
(U/L)
Peak TB
(mg/dL)
Time of
reactivation
Type of
antivirals
Clinical
outcome
Westhoﬀ
et al. (2003) [24]
73 M DLC anti HBs+ R NR NR After 5
cycles
Lamivudine Liver-related
death
anti-HBc+
Sarrechia
et al. (2005) [25]
53 M CLL anti-HBs+ R 2110 17 After 3
months
Lamivudine Liver-related
death
anti-HBc+
Law
et al. (2005) [26]
67 M NHL anti-HBs+ R-CHOP 2204 NR After 8
cycles
Lamivudine Liver-related
death
anti-HBc+
Niscola
et al. (2005) [27]
51 M CLL anti-HBs + R NR NR After 7
months
Lamivudine Liver-related
death
anti-HBc+
Sera
et al. (2006) [28]
59 M NHL anti-HBs+ R+ VP16+ P
+ Dex
359 26.4 2 months
after
stopping R
Lamivudine Liver-related
deathanti-HBc+
Ozgonenel
et al. (2006) [29]
21 M DCL NR R-CHOP NR NR After
3 cycles
Lamivudine Liver-related
death
Yamagata
et al. (2007) [30]
54 M DCL anti-HBc+ R-CHOP 531 After
7 cycles
Lamivudine Liver-related
death
Dillon
et al. (2008) [22]
21 F DCL NR R-CHOP 10  UL NR After
4 cycles
Lamivudine Liver-related
death
Garcia-Rodriguez
et al. (2008) [23]
68 F DCL NR R-CHOP 97 14 1 year
after
6 cycles
Lamivudine Liver-related
death
Garcia-Rodriguez
et al. (2008) [23]
53 F FL NR R-CHOP 177 1.2 9 months
after
3 cycles
Lamivudine,
then Entecavir
Alive
Colson
et al. (2008) [14]
48 M DCL anti-HBs+ R-CHOP 1800 WNL After
4 cycles
Entecavir Alive
anti-HBc+
Yeo
et al. (2009) [1]
77 M DCL anti-HBc+ R-CHOP 2110 4.2 After
6 cycles
Lamivudine Liver-related
death
Yeo
et al. (2009) [1]
58 M DCL anti-HBc+ R-CHOP 362 1.1 After
5 cycles
Lamivudine Alive
Yeo
et al. (2009) [1]
46 M DCL anti-HBc+ R-CHOP 809 0.5 After
6 cycles
Lamivudine Malignancy-
related
death
Yeo
et al. (2009) [1]
63 M DCL anti-HBc+ R-CHOP 649 0.32 After
6 cycles
Lamivudine Alive
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CLL, chronic lymphocytic leukemia; Dex, dexamethasone; DCL,
diﬀuse large cell lymphoma; FL, follicular lymphoma; NHL, non-hodgkin’ lymphoma; NR, no reported; P, prednisone; R, rituximab; ULN, upper
limit of normal; VP16, etoposide; WNL, within normal limits; , times.
a All the patients have HBsAg if serology is reported.
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and safety of entecavir in the treatment and reversal
of severe HBV reactivation and provides evidence for
the use of this drug in HBV reactivation associated
with a high viral load, as suggested by European guide-
lines [4]. It also demonstrates that, in addition to
HBsAg testing, anti-HBc and anti-HBs determinations
have to be included in the screening process prior to
the use of rituximab or other potent monoclonal anti-
bodies, in order to prevent the development of HBV
reactivation.Note added in proof
Two months after this manuscript was submitted the
patient remains asymptomatic, and his labs showed
HBsAg negative, normal ALT levels and undetectable
HBV DNA.
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